Latest Updates on the Healthcare Sector: Complementary Research on NxStage Medical, PhotoMedex, Rockwell Medical, Semler and Stereotaxis
NEW YORK, February 25, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including NxStage Medical (NASDAQ: NXTM), PhotoMedex (NASDAQ: PHMD), Rockwell Medical (NASDAQ: RMTI), Semler (NASDAQ: SMLR), and Stereotaxis (NASDAQ: STXS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
NXTM Research Report: ( http://get.analystsreview.com/pdf/?c=NxStage%20Medical&d=25-Feb-2015&s=NXTM ),
PHMD Research Report: ( http://get.analystsreview.com/pdf/?c=PhotoMedex&d=25-Feb-2015&s=PHMD ),
RMTI Research Report: ( http://get.analystsreview.com/pdf/?c=Rockwell%20Medical&d=25-Feb-2015&s=RMTI ),
SMLR Research Report: ( http://get.analystsreview.com/pdf/?c=Semler&d=25-Feb-2015&s=SMLR ),
STXS Research Report: ( http://get.analystsreview.com/pdf/?c=Stereotaxis&d=25-Feb-2015&s=STXS ).
============
--
Analyst Update: Financial Results, Acquisitions, Upcoming Earnings and FDA Approval
Reviewed by: Rohit Tuli, CFA®
US stocks rose to record levels on Tuesday after Federal Reserve Chair Janet Yellen suggested that the central bank is not likely to begin raising interest rates for at least the next couple monetary policy meetings; and intends a rate hike only when they are "reasonably confident" that annual inflation is moving back toward their 2 percent target. The S&P 500 gained 5.82 points, or 0.28%, to end at 2,115.48, and the Dow Jones Industrial Average edged up 92.35 points or 0.51% to 18,209.19. The tech-heavy NASDAQ advanced for the tenth straight session, up 7.15 points or 0.14% to close at 4,968.12. Meanwhile, most of Europe's benchmark stock indices closed higher on Tuesday, following reports that Eurozone finance ministers, the European Commission, the European Central Bank and the International Monetary Fund have approved Greece's request for an extended €240 billion ($273 billion) bailout. Germany's DAX 30 rose 0.67% to 11,205.74, while, FTSE 100 gained 0.54% to 6,949.63. France's CAC 40 gained 0.50% to 4,886.44.
NxStage Medical, Inc (NxStage Medical) will release its financial results for the fourth quarter and full year ended December 31, 2014, on Thursday, February 26, 2015, before the financial markets open. The earnings release will be followed by a conference call at 9:00 a.m. ET on the same day to discuss its financial results.
PhotoMedex, Inc. (PhotoMedex) announced the sale of its LCA-Vision subsidiary to Vision Acquisition, LLC for $40 million in cash for net proceeds of approximately $35.3 million (excluding working capital adjustments and professional fees).
Rockwell Medical, Inc.'s (Rockwell Medical) drug Triferic has been approved by U.S. Food & Drug Administration (FDA) for commercial sale as an iron replacement product to maintain hemoglobin in adult patients with hemodialysis dependent chronic kidney disease.
Semler Scientific, Inc. (Semler), an emerging medical risk assessment company, reported 2014 fourth quarter and full year 2014 financial results with revenue growth of 35% YoY and 60% YoY for the quarter and the full-year, respectively.
Stereotaxis, Inc. (Stereotaxis) is scheduled to release financial results for its 2014 fourth quarter and full year ended December 31, 2014 on Wednesday, February 25, 2015 after the close of the U.S. financial markets. A conference call will be webcast at 4:30 p.m. ET (1:30 p.m. PT) on the same day to discuss the Company's results and corporate developments.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article